Table of Contents
<< Previous Issue | Dec 2014 (Vol: 2014, Issue: 12) | Next Issue >> |
- Section: Licensing
-
Pfizer Pays Merck KGaA US$850 M Upfront to Compete in Immuno-Oncology
- Section: Mergers & Acquisitions
-
Allergan Rebuffs Valeant and Agrees to US$66 B Actavis Deal
-
Otsuka Continues Overseas Expansion with US$3.5 B Avanir Buyout
-
Merck & Co. Agrees to Buy Cubist in US$9.5 B Deal to Strengthen its Acute Care Portfolio